InMed Pharmaceuticals Inc.

INM | NASDAQ

Price Alert Chart Builder DCF Calculator

$13.21

-$4.29 (-24.53%)

At close: Nov 5, 2026, 4:00 PM ET

$13.53

+$0.32 (+2.42%)

After-hours: Nov 5, 2026, 4:28 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $7.26M

Enterprise Value $-1.13B

Beta 0.95

Average Volume 708.41K

Shares Outstanding (Diluted) 5.47M

Shares Change YoY 38.31%

Institutional Ownership N/A

Exchange NASDAQ

ISIN CA4576377002

Price Performance

Price Change 1M 893.2%

Price Change 3M 823.8%

Price Change 6M 1796.9%

Price Change YTD 1146.2%

Price Change 1Y 672.5%

Price Change 3Y 54.0%

Price Change 5Y -98.2%

1M CAGR (ann.) 26.8%

1Y CAGR (ann.) -5.4%

5Y CAGR (ann.) -70.2%

All-Time CAGR -51.3%

Valuation

PE Ratio -0.53

Forward PE N/A

PEG Ratio -0.01

Forward PEG 0.01

PS Ratio 0.00

Forward PS N/A

PB Ratio -0.01

P/FCF Ratio -0.01

P/Adj. FCF Ratio -0.01

P/OCF Ratio -0.01

EV/Sales -0.55

EV/EBIT 104.22

EV/EBITDA 112.25

EV/FCF 0.98

Earnings Yield -188.6%

FCF Yield -11964.1%

Adj. FCF Yield -13980.8%

Financial Health

Net Cash $1.13B

Total Debt $0

Cash & Short-Term Investments $1.13B

Total Assets $1.31B

Current Ratio 504.31

Quick Ratio 504.31

Debt / Equity Ratio 0.00

Debt / EBITDA -0.00

Debt / FCF -0.00

OCF / Debt N/A

Interest Coverage -1,023.20

Altman Z-Score 2.57

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 14.9%

Operating Profit Margin -0.5%

EBITDA Margin -0.5%

Net Profit Margin -0.6%

FCF Margin -55.9%

Adj. FCF Margin -65.3%

SBC / Revenue 9.4%

SBC Impact (per share) -16.9%

Returns

Return on Assets -1.0%

Return on Equity 4.5%

Return on Invested Capital -0.8%

Return on Capital Employed -0.8%

Return on Tangible Assets -1.0%

Historical Growth (CAGR)

Revenue CAGR 3Y 615.0%

Revenue CAGR 5Y 99.1%

Revenue CAGR 10Y 54.3%

EPS CAGR 3Y 66.1%

EPS CAGR 5Y 91.9%

EPS CAGR 10Y 23.6%

FCF CAGR 3Y -147.2%

FCF CAGR 5Y -95.6%

FCF CAGR 10Y -51.4%

Analyst Forecasts

Analyst Rating Hold

Analyst Count 0

EPS Growth Next 3Y N/A

Revenue Growth Next 3Y N/A

Earnings Date Feb 16, 2027

EPS Estimate (next Q) -$135.47

EPS Growth Est (next Q) 26463.6%

Revenue Est (next Q) $300K

Revenue Growth Est (next Q) -73.0%

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $0.00

Price Target Upside N/A

Cash Flow

Operating Cash Flow $-1.15B

Free Cash Flow $-1.15B

Adj. Free Cash Flow $-1.34B

FCF Per Share -$210.30

OCF Per Share -$210.30

OCF/S Ratio -55.9%

Income Statement

Revenue $2.06B

Gross Profit $306.75M

Operating Income $-10.95M

EBITDA $-10.02M

Net Income $-13.16M

EPS (Diluted) -$3.30

Revenue / Employee $343.15M

Profit / Employee $-2.19M

Employees 6